<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00263484</url>
  </required_header>
  <id_info>
    <org_study_id>SQMM01(dtZ)</org_study_id>
    <nct_id>NCT00263484</nct_id>
  </id_info>
  <brief_title>Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma</brief_title>
  <acronym>dtZ</acronym>
  <official_title>An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gleneagles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tan Tock Seng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christian Medical College, Vellore, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tata Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gleneagles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lower than conventional doses of
      dexamethasone and thalidomide; and a higher dosing frequency of zoledronic acid are effective
      in the treatment of newly-diagnosed multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with newly-diagnosed multiple myeloma (MM) may be treated using monthly cycles of
      dexamethasone plus thalidomide (DT). Unfortunately, the use of conventional doses of DT is
      associated with significant treatment-related morbidity and mortality, which is comparable to
      that observed with conventional chemotherapy. Hence, for safety reasons, patients frequently
      receive lower than conventional doses of DT (i.e. dt), and potentially experience a poorer
      anti-MM effect. The highly-potent aminobisphosphonate, zoledronic acid (Z), has been shown in
      pre-clinical mouse models to exhibit an impressive anti-MM effect. It is therefore possible
      to combined dt with Z (i.e. dtZ) to enhance the efficacy of (lower dose) dt. In addition, the
      anti-tumor effect of dtZ may potentially be augmented by using Z at a higher (three-weekly)
      dosing frequency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. To determine response rates (RR) and disease progression rates in all MM patients treated with dtZ regimen.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess overall survival (OS) in all patients treated with dtZ regimen.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of incidence of skeletal related events (SREs).</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of percent change in renal function in all patients.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>&quot;dtZ&quot; regimen, Initial therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To test the efficacy of the &quot;dtZ&quot; regimen in previously untreated patients with multiple myeloma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>&quot;dtZ&quot; regimen, Initial therapy</arm_group_label>
    <other_name>DEXAMETHASONE BEACONS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>&quot;dtZ&quot; regimen, Initial therapy</arm_group_label>
    <other_name>THALOMID (PHARMION)</other_name>
    <other_name>THADO (TTY)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <description>4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>&quot;dtZ&quot; regimen, Initial therapy</arm_group_label>
    <other_name>ZOMETA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at or above 21 years

          -  Clinical diagnosis of MM

          -  Active MM with measurable disease

          -  Signed written informed consent

          -  Signed consent for drug safety program for thalidomide

        Exclusion Criteria:

          -  Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)

          -  Patients with Indolent MM (IMM), or Smouldering MM (SMM)

          -  Known hypersensitivity (including severe cutaneous reactions) to d, t or Z

          -  Fulminant sepsis

          -  Females in the reproductive age group who refuse contraception

          -  Pregnancy

          -  24 hr urinary creatinine clearance time (CCT) &lt;30 ml/min

          -  Previous renal transplantation

          -  Severe peripheral neuropathy

          -  Recurrent DVT or PE

          -  Severe arrhythmias and cardiac conduction disorders

          -  Liver dysfunction of active viral hepatitis

          -  Osteonecrosis of the jaws (ONJ)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerrard Teoh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gleneagles Hospital, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Kwangju</city>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center, Seoul, South Korea</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center, University of Ulsan, South Korea</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre, Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gleneagles Hospital, Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>258500</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital, Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <removed_countries>
    <country>Malaysia</country>
  </removed_countries>
  <link>
    <url>http://www.cbd.sg</url>
    <description>Clinic for Blood Disorders and Research (CBD), Gleneagles Hospital, Singapore</description>
  </link>
  <reference>
    <citation>Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002 Feb;116(2):278-90.</citation>
    <PMID>11841428</PMID>
  </reference>
  <reference>
    <citation>Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003 Oct 15;98(8):1735-44.</citation>
    <PMID>14534891</PMID>
  </reference>
  <reference>
    <citation>Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002 Nov 1;20(21):4319-23.</citation>
    <PMID>12409330</PMID>
  </reference>
  <reference>
    <citation>Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003 Jan 1;21(1):16-9.</citation>
    <PMID>12506164</PMID>
  </reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2005</study_first_submitted>
  <study_first_submitted_qc>December 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2005</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Gerrard Teoh</name_title>
    <organization>Gleneagles Hospital, Singapore</organization>
  </responsible_party>
  <keyword>Steroids, Fluorinated</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Bisphosphonates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

